Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 0.68 |
| ▸ | PTGS2 | P35354 | 8/20 | 0.59 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3276806 | 0.87 | PTGS1 (0.79) | PTGS1PTGS2PDPK1CYP2C9 | |
| SCHEMBL29503530 | 0.87 | PTGS1 (0.79) | PTGS1PTGS2PDPK1MAPTCYP2C9 | |
| SCHEMBL2695601 | 0.85 | PTGS1 (0.80) | PTGS1PTGS2PDPK1CYP2C9 | |
| SCHEMBL3277751 | 0.83 | PTGS1 (0.49) | PTGS1PTGS2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6451398 | 0.82 | PTGS1 (1.00) | PTGS1PTGS2PDPK1NPC1RAB9A | |
| SCHEMBL22289006 | 0.82 | PTGS1 (0.71) | PTGS1PTGS2PDPK1CYP3A4CYP2C9 | |
| SCHEMBL3473104 | 0.79 | PTGS2 (0.62) | PTGS1PTGS2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3278428 | 0.79 | PTGS1 (0.76) | PTGS1PTGS2PDPK1SMN1; SMN2MAPT | |
| SCHEMBL14198874 | 0.79 | PTGS1 (0.76) | PTGS1PTGS2PDPK1NPC1RAB9A | |
| SCHEMBL21879554 | 0.79 | PTGS1 (0.70) | PTGS1PTGS2PDPK1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700655-B2 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-04-20 | — | — | US | disclosed |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-04-17 | — | — | US | disclosed |
| US-20070185059-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185110-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20060122243-A1 | Antiallergic | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-06-08 | — | — | US | disclosed |
| US-20060111409-A1 | Medicament for treatment of diabetes | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-25 | — | — | US | disclosed |
| US-20060100257-A1 | Inhibitors against the activation of ap-1 and nfat | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-20060019958-A1 | Immunity-related protein kinase inhibitors | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-01-26 | — | — | US | disclosed |
| EP-1514544-A1 | ANTIALLERGIC | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-16 | — | — | EP | disclosed |
| EP-1512396-A1 | INHIBITORS AGAINST THE ACTIVATION OF AP-1 AND NFAT | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| EP-1510210-A1 | IMMUNITY-RELATED PROTEIN KINASE INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| EP-1510207-A1 | THERAPEUTIC DRUG FOR DIABETES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019958-A1 | Immunity-related protein kinase inhibitors | MAP3K1, MAP3K7, MAP3K8 | PTGS1 653/4885PTGS2 1119/4885PDPK1 184/4885 |
| US-20060111409-A1 | Medicament for treatment of diabetes | XDH, SLC5A1, SLC5A2 | PTGS1 658/4885PTGS2 1369/4885PDPK1 4080/4885 |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | NAT1, EPX, HRH2 | PTGS1 89/4885PTGS2 219/4885PDPK1 4171/4885 |
| US-20060122243-A1 | Antiallergic | EPX, NAT1, HNMT | PTGS1 101/4885PTGS2 286/4885PDPK1 4114/4885 |
| US-20060100257-A1 | Inhibitors against the activation of ap-1 and nfat | NFATC1, AP1G1, ATF1 | PTGS1 614/4885PTGS2 1640/4885PDPK1 816/4885 |
| US-20070185110-A1 | Antiallergic agents | NAT1, EPX, AHR | PTGS1 113/4885PTGS2 246/4885PDPK1 4198/4885 |
| US-20070185059-A1 | Antiallergic agents | NAT1, EPX, AHR | PTGS1 117/4885PTGS2 271/4885PDPK1 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.